Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A study to learn if UCB3101 is safe and how it moves through the body of healthy participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: UCB3101
Drug: Placebo

First Posted Date: 2024-06-14

Last Posted Date: 2025-05-09

Lead Sponsor: UCB Biopharma

Target Recruit Count: 88

Registration Number: 2023-504586-24-00

Locations: 🇧🇪
SGS Belgium, Edegem, Belgium

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Phase 3

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: rozanolixizumab

First Posted Date: 2024-08-06

Last Posted Date: 2025-07-04

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 12

Registration Number: NCT06540144

Locations: 🇯🇵
Mg0008 20343, Sagamihara, Japan
🇮🇹
Mg0008 40290, Bologna, Italy
🇮🇹
Mg0008 40144, Milano, Italy

and more 6 locations

A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Minzasolmin tablet formulation under fasting condition
Drug: Minzasolmin Granules in capsule under fasting condition
Drug: Minzasolmin tablet formulation under fed condition

First Posted Date: 2024-08-01

Last Posted Date: 2024-11-25

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 18

Registration Number: NCT06533475

Locations: 🇩🇪
Up0152 1001, Berlin, Germany

A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Zilucoplan

First Posted Date: 2024-07-19

Last Posted Date: 2024-12-06

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 14

Registration Number: NCT06511076

Locations: 🇳🇱
DV0012 1, Groningen, Netherlands

A study to learn how bimekizumab works in people with moderate to severe plaque psoriasis.

Recruiting

Conditions: Psoriatic arthritis
Moderate to Severe Plaque Psoriasis

Interventions: Drug: bimekizumab

First Posted Date: 2024-08-15

Last Posted Date: 2025-06-25

Lead Sponsor: UCB Biopharma

Target Recruit Count: 46

Registration Number: 2023-506333-29-00

Locations: 🇩🇪
Goethe University Frankfurt, Frankfurt Am Main, Germany
🇩🇪
Medical Center - University Of Freiburg, Freiburg Im Breisgau, Germany
🇩🇪
Praxis Hoffmann, Witten, Germany

and more 6 locations

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

Phase 3

Completed

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Zilucoplan

First Posted Date: 2024-06-24

Last Posted Date: 2025-02-17

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 31

Registration Number: NCT06471361

Locations: 🇺🇸
Dv0013 50628, New Haven, Connecticut, United States
🇺🇸
Dv0013 50634, Tampa, Florida, United States
🇺🇸
Dv0013 50648, Columbia, Missouri, United States

and more 8 locations

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Phase 3

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Zilucoplan

First Posted Date: 2024-05-30

Last Posted Date: 2025-03-13

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 8

Registration Number: NCT06435312

Locations: 🇬🇧
Mg0015 40736, London, United Kingdom
🇺🇸
Mg0015 50168, Chicago, Illinois, United States
🇺🇸
Mg0015 50574, Denton, Texas, United States

and more 6 locations

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: bimekizumab
Drug: placebo
Drug: ustekinumab

First Posted Date: 2024-05-22

Last Posted Date: 2025-06-27

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 168

Registration Number: NCT06425549

Locations: 🇺🇸
Ps0021 50162, Fountain Valley, California, United States
🇺🇸
Ps0021 50161, Los Angeles, California, United States
🇺🇸
Ps0021 50196, Northridge, California, United States

and more 43 locations

A study to learn about the safety of long-term treatment with brivaracetam in children and young adults with childhood or juvenile absence epilepsy

Phase 3

Recruiting

Conditions: Juvenile Absence Epilepsy
Childhood Absence Epilepsy

First Posted Date: 2024-07-19

Last Posted Date: 2025-04-15

Lead Sponsor: UCB Biopharma

Target Recruit Count: 31

Registration Number: 2023-508095-11-00

Locations: 🇸🇰
In Medic s.r.o, Bardejov, Slovakia
🇸🇰
Konzilium s.r.o., Nova Dubnica, Slovakia
🇪🇸
Fundacio Assistencial De Mutua De Terrassa Fpc, Terrassa, Spain

and more 11 locations

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: UCB9741
Drug: Placebo

First Posted Date: 2024-03-18

Last Posted Date: 2025-01-31

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 40

Registration Number: NCT06315335

Locations: 🇺🇸
Up0118 10001, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy